Viewing data from:

ORPHENADRINE CITRATE

ANDA

ORPHENADRINE CITRATE | A040249 | RISING PHARMA HOLDINGS INC

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Orphenadrine Citrate (2023)

Total Spending

$533K

Total Claims

7,774

Beneficiaries

5,307

Avg Cost/Unit

$7.02

Spending Trend

$485K(2019)→$645K(2020)→$550K(2021)→$747K(2022)→$533K(2023)

YoY Change:+26.5%

5yr CAGR:+12.3%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

API Supply Chain4 active DMFs3 inactive

3 active API suppliers hold Drug Master Files for this ingredient.

W R GRACE AND CO -CONNORPHENADRINE CITRATE USP

DMF 57221985

PROCOS SPAORPHENADRINE CITRATE

DMF 149712000

R L FINE CHEM PVT LTDORPHENADRINE CITRATE

DMF 339012019

R L FINE CHEM PVT LTDORPHENADRINE CITRATE

DMF 384562023

ORGAMOL SAInactiveORPHENADRINE CITRATE AND ORPHENADRINE HCL.

DMF 48111983

3M PHARMACEUTICALSInactiveORPHENADRINE CITRATE

DMF 71081987

IROPHARM LTDInactiveORPHENADRINE CITRATE

DMF 78371988

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Approval Letters

1 letter from Drugs@FDA

Date	Submission	Document
Jan 29, 1999	ORIG -1	View Letter (PDF)

Source: Drugs@FDA application documents.

Products (1)

#001 — 100MG

0 patents0 exclusivities▴

TABLET, EXTENDED RELEASE;ORAL | Approved: Jan 29, 1999

No patent or exclusivity listings for this strength.